Our laboratory was founded 50 years ago, when Pierre Fabre developed the Cyclo 3 drug. Since then, a significant part of the turnover from our pharmaceutical activities has been spent on R&D for innovative treatments. We often work in partnership with public or private research laboratories to develop the drugs of tomorrow, mainly in the field of onco-hematology, neuropsychiatry and dermatology.
Since Navelbine (vinorelbine) was first developed in partnership with the French National Centre for Scientific Research (CNRS) in the 1980s, Pierre Fabre has become recognized by oncologists all over the world. Today, oncology, be it in the areas of solid or liquid tumors, attracts the lion's share of Pierre Fabre Pharmaceutical investments.
As a long-standing partner of dermatologists, we address the main dermatological pathologies, such as acne, mycosis, psoriasis, atopical dermatitis and alopecia. It is our ambition to become a global player in pediatric dermatology, thanks in particular to the development of a specific drug to treat pediatric hemangioma.
The presence of Pierre Fabre in the field of neuropsychiatry dates back to the late 1990s, with the development of milnacipran, a molecule used to treat depression in Europe and fibromyalgia in the United States, where its enantiomer, levomilnacipran, is marketed for treating major depressive episodes.